SeekingAlphaAugust 23, 2026 at 1:52 AM NY12 days ago
Prelude Therapeutics: A Prognosis After Year-Long Rally
Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha
Companies in This Story
Related Stories
Which dow jones stocks are moving on Friday?
ChartMill4 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill4 hours ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo4 hours ago
Sector Update: Financial
Yahoo6 hours ago
Should You Buy, Sell or Hold PVH Stock Post Q2 Earnings?
Yahoo6 hours ago